Docetaxel News and Research

RSS

Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.

Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels

For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, reports a study in the April issue of The Journal of Urology, an Official Journal of the American Urological Association.

17 Apr 2024

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC).

15 Feb 2024

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with docetaxel.

5 Feb 2024

Receptor protein found to be a key player in prostate cancer cells' drug resistance

Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate.

22 Jan 2024

New approach using ultrasound-guided drug delivery effectively targets lymph node metastasis

Researchers at Tohoku University have discovered a new approach for treating lymph node metastasis. Anticancer drugs are administered directly into the LNs under ultrasound guidance (Lymphatic Drug Delivery System or LDDS) to target sentinel lymph nodes (LNs) and generate antitumor effects locally, preventing distant metastasis.

12 Jan 2024

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomized clinical trial in China.

8 Nov 2023

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

The safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib.

2 Nov 2023

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis.

1 Nov 2023

Modular nanoparticles developed for targeted drug delivery and neutralizing biological agents

Engineers at the University of California San Diego have developed modular nanoparticles that can be easily customized to target different biological entities such as tumors, viruses or toxins.

30 Oct 2023

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.

26 Oct 2023

Chemotherapy drug may promote cancer growth by injuring surrounding cells

A standard chemotherapy drug injures surrounding non-cancer cells, which can then awakens dormant cancer cells and promotes cancer growth, according to a new study publishing September 12th in the open access journal PLOS Biology by Ramya Ganesan of Emory University, US, and colleagues.

12 Sep 2023

Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLC

The oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

From AMGEN 1 Sep 2023

New treatment approach shows promise in reversing hormone resistance in breast cancer

A collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively.

9 Aug 2023

Assessing the role of Docetaxel post-chemoimmunotherapy for patients with NSCLC

A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)."

8 Jun 2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.

5 Jun 2023

Breast cancer patients experience more severe CIPN symptoms with paclitaxel

Chemotherapy-induced peripheral neuropathy (CIPN) – nerve pain, tingling, or numbness in the hands or feet – is a common side effect of certain cancer treatments, including two drugs frequently used to treat cancer – the taxanes paclitaxel and docetaxel.

31 May 2023

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology's annual meeting.

23 May 2023

Clinical trial of ENZAMET shows promising results for men with advanced prostate cancer

A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.

28 Mar 2023

New funding to accelerate development of potential anti-cancer compound into the clinic

For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) to develop next-generation anti-cancer agents.

28 Feb 2023